ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Prof Tsimberidou speaks to ecancer about the WIN consortium's goals and successes so far.
She describes the importance of diversity within the WIN consortium in particular from a genetic perspective.
Prof Tsimberidou concludes with why the WIN consortium is important to her, and what her personal goals are for cancer research.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Addressing the rise of multiple myeloma in Rwanda
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in radiology Tanzania
The advantages of IORT for early breast cancer treatment
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Moving to the future: Artificial intelligence in surgery